The content on this site is intended for healthcare professionals only
Prof Nicoletta Colombo speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about the recent data on the use of immunotherapy in cervical and endometrial cancers.
She states there are several phase II trials that have achieved a response rate of close to 50 percent in patients with MSI high tumours when treated with immune checkpoint inhibitors.
Prof Colombo believes this field is heading towards the use of combination approaches and describes some ongoing phase III trials that are investigating the combination of immune checkpoint inhibitors.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas
EAU 2024: Bladder cancer latest
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert round up July 28th to August 3rd, 2023
Gynaecological cancer: New targets and immunotherapy developments
The current status of multiple myeloma diagnosis and treatment
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
